Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Despite High Rates of Remission, Treatment of IDH-Mutant AML with Hypomethylating Agents and Venetoclax Is Associated with Frequent Treatment Delays, Modifications, and Transfusions

Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, Gaurav Gupta, Prabhakar Borge, Ellin Berman, Mark Blaine Geyer, Aaron D. Goldberg, Tamanna Haque, Raajit K. Rampal, Jae H. Park, Lindsey E. Roeker, Martin S. Tallman, Eytan M. Stein

Blood (2023) 142 (Supplement 1): 1519.

https://doi.org/10.1182/blood-2023-182012

Published: 2023

Journal Articles

Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia

Blood (2022) 140 (Supplement 1): 2137–2139.

https://doi.org/10.1182/blood-2022-157193

Published: 2022

Journal Articles

How I treat chronic-phase chronic myelogenous leukemia

Ellin Berman

Blood (2022) 139 (21): 3138–3147.

https://doi.org/10.1182/blood.2021011722

Published: 2022

Journal Articles

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna, John N. Allan, Lori Leslie, John M. Pagel, Krish Patel, Anders Osterborg, Daniel Wojenski, Manali Kamdar, Scott F. Huntington, Matthew S. Davids, Jennifer R. Brown, Darko Antic, Ryan Jacobs, Inhye E. Ahn, Jeffrey Pu, Krista M. Isaac, Paul M. Barr, Chaitra S. Ujjani, Mark B. Geyer, Ellin Berman, Andrew D. Zelenetz, Nikita Malakhov, Richard R. Furman, Michael Koropsak, Neil Bailey, Lotta Hanson, Guilherme F. Perini, Shuo Ma, Christine E. Ryan, Adrian Wiestner, Craig A. Portell, Mazyar Shadman, Elise A. Chong, Danielle M. Brander, Suchitra Sundaram, Amanda N. Seddon, Erlene Seymour, Meera Patel, Nicolas Martinez-Calle, Talha Munir, Renata Walewska, Angus Broom, Harriet Walter, Dima El-Sharkawi, Helen Parry, Matthew R. Wilson, Piers E. M. Patten, José-Ángel Hernández-Rivas, Fatima Miras, Noemi Fernández Escalada, Paola Ghione, Chadi Nabhan, Sonia Lebowitz, Erica Bhavsar, Javier López-Jiménez, Daniel Naya, Jose Antonio Garcia-Marco, Sigrid S. Skånland, Raul Cordoba, Toby A. Eyre

Blood (2020) 136 (10): 1134–1143.

https://doi.org/10.1182/blood.2020006965

Published: 2020

Includes: Supplemental data

Journal Articles

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Catherine C. Smith, MD, Mark J. Levis, MD, Alexander E. Perl, MD, Giovanni Martinelli, MD, Andreas Neubauer, MD, Ellin Berman, MD, Pau Montesinos, MD PhD, Maria R. Baer, MD, Richard A. Larson, MD, Wen-Chien Chou, MD, PhD, Hisayuki Yokoyama, MD PhD, Christian Recher, MD PhD, Sung-Soo Yoon, MD PhD, Jason E. Hill, Matt Rosales, Erkut Bahceci

Blood (2019) 134 (Supplement_1): 14.

https://doi.org/10.1182/blood-2019-122620

Published: 2019

Journal Articles

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Blood (2019) 134 (Supplement_1): 3934.

https://doi.org/10.1182/blood-2019-124178

Published: 2019

Journal Articles

Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies

Aaron D Goldberg, MD, Troy Z. Horvat, PharmD, BCOP, Meier Hsu, MS, Sean M. Devlin, PhD, Bernadette M. Cuello, BSN, MSN, NP, RN, Ryan J. Daley, PharmD, BCOP, Amber C. King, PharmD, BCOP, Larry W Buie, PharmD, BCOP, FASHP, Jacob L Glass, MDPhD, Michael J. Mauro, MD, Eytan M. Stein, MD, Ellin Berman, MD, Virginia M. Klimek, MD, Martin S. Tallman, MD

Blood (2017) 130 (Supplement 1): 1353.

https://doi.org/10.1182/blood.V130.Suppl_1.1353.1353

Published: 2017

Journal Articles

Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles

Blood (2017) 130 (Supplement 1): 891.

https://doi.org/10.1182/blood.V130.Suppl_1.891.891

Published: 2017

Journal Articles

Molecular Profiling in Extramedullary Acute Myeloid Leukemia Reveals Distinct Subgroups Defined By Mutations in KIT and RUNX1

Aaron D Goldberg, MD, Noushin Farnoud, PhD, Cody Goldberger, Minal Patel, BA, Christopher Famulare, MS, Juan Medina, Raajit K. Rampal, MD PhD, Ross L. Levine, MD, Ellin Berman, MD, Yanming Zhang, MD, Filiz Sen, MD, Elli Papaemmanuil, PhD, Martin S. Tallman, MD

Blood (2017) 130 (Supplement 1): 2663.

https://doi.org/10.1182/blood.V130.Suppl_1.2663.2663

Published: 2017

Journal Articles

Activation Levels of b-Catenin Signaling in Osteoblasts Define a Threshold for the Development of Myeloid Neoplasia of Variable Severity

Ioanna Mosialou, PhD, Alvaro Cuesta-Dominiguez, PhD, Govind Bhagat, MD, Ellin Berman, MD, Azra Raza, MD, Stavroula Kousteni, PhD

Blood (2017) 130 (Supplement 1): 2946.

https://doi.org/10.1182/blood.V130.Suppl_1.2946.2946

Published: 2017

Journal Articles

Clinical Relevant Alterations Identified By Comprehensive Genomic Profiling Can Potentially Improve Therapeutic Option and Change Prognosis in Hematologic Malignancies

Blood (2016) 128 (22): 5109.

https://doi.org/10.1182/blood.V128.22.5109.5109

Published: 2016

Journal Articles

Targeting the Osteoblast in Myelodysplasia and Acute Myeloid Leukemia

Masahiro Marshall Nakagawa, Aruna Kode, Sanil J Manavalan, Govind Bhagat, MD, Julie Teruya-Feldstein, MD, Azra Raza, MD, Ellin Berman, MD, Stavroula Kousteni

Blood (2015) 126 (23): 2551.

https://doi.org/10.1182/blood.V126.23.2551.2551

Published: 2015

Journal Articles

AUY922, a Heat Shock Protein 90 (Hsp90) Inhibitor, Demonstrates Activity in Patients with Myeloproliferative Neoplasms (MPNs)

Gabriella Hobbs, MD, Rivka Litvin, Jihae Ahn, Anna Sophia Mckenney, Michael J. Mauro, MD, Martin S Tallman, MD, Ellin Berman, MD, Mark Lawrence Heaney, MD PhD, Ross L. Levine, MD, Raajit K. Rampal, MD, PhD

Blood (2015) 126 (23): 4075.

https://doi.org/10.1182/blood.V126.23.4075.4075

Published: 2015

Journal Articles

Foxo1 Expressed in Osteoblasts Promotes the Leukemogenic Properties of β-Catenin By Activating Notch Signaling

Aruna Kode, Ioanna Mosialou, Sanil J Manavalan, Julie Teruya Feldstein, Govind Bhagat, MD, Ellin Berman, MD, Stavroula Kousteni

Blood (2014) 124 (21): 2356.

https://doi.org/10.1182/blood.V124.21.2356.2356

Published: 2014

Journal Articles

Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts

Blood (2014) 124 (18): 2834–2846.

https://doi.org/10.1182/blood-2013-07-517219

Published: 2014

Includes: Supplemental data

Journal Articles

High-Dose Cytarabine Monotherapy Versus Intermediate Or High-Dose Cytarabine In Combination With Other Agents As Second-Line Salvage Therapy In Patients With Acute Myeloid Leukemia Who Did Not Respond To Initial Induction Therapy

Thu Oanh T Dang, PharmD, BCOP, Patrick Hilden, MS, Sean M. Devlin, PhD, Raajit K. Rampal, M.D., Ph.D., Ross L. Levine, MD, Ellin Berman, MD, Virginia M. Klimek, M.D., Nelly G. Adel, PharmD, BCOP, BCPS, Martin S. Tallman, MD

Blood (2013) 122 (21): 2695.

https://doi.org/10.1182/blood.V122.21.2695.2695

Published: 2013

Journal Articles

Stem Cell Transplant Versus Chemotherapy in Older Adults with Acute Myelogenous Leukemia In First Remission

Ellin Berman, MD, Molly Maloy, MA, Sean M. Devlin, PhD, Esperanza B Papadopoulos, MD, Ann A. Jakubowski, MD, PhD

Blood (2013) 122 (21): 2146.

https://doi.org/10.1182/blood.V122.21.2146.2146

Published: 2013

Journal Articles

Chronic Myeloid Leukemia After Adjuvant Treatment For Breast Cancer: Is It Therapy Related?

Ashwin Kishtagari, MBBS, Isaac Alexander Bowman, MD, Martin S. Tallman, MD, Dan Douer, MD, Ellin Berman, MD, Peter G. Maslak, M.D., Renier J Brentjens, MD, PhD, Eytan M Stein, MD

Blood (2013) 122 (21): 2740.

https://doi.org/10.1182/blood.V122.21.2740.2740

Published: 2013

Journal Articles

Micafungin Versus Posaconazole Anti-Fungal Prophylaxis in Adult Patients with Acute Leukemia Undergoing Induction Chemotherapy

Elizabeth Halton, RN, MS, ANP, Dick Chung, BS, Kun Xiao, MS, MPH, Hilda Quintanilla, RN, MS, ANP, Christina Baldwin, RN, MS, ANP, Pamela Baird, RN, MS, ANP, Ellin Berman, MD, Renier J Brentjens, MD, PhD, Mark Heaney, MD, PhD, Joseph G. Jurcic, MD, Nicole Lamanna, MD, Todd L. Rosenblat, MD, Rana Kaplan, MD, Genovefa Papanicolaou, MD, Mark G. Frattini, MD, PhD

Blood (2012) 120 (21): 3556.

https://doi.org/10.1182/blood.V120.21.3556.3556

Published: 2012

Journal Articles

Outcome of Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia and Normal Cytogenetics (NC-AML) According to Presence of FLT-3 Internal Tandem Duplication (FLT-3ITD) At the Time of Diagnosis

Ellin Berman, MD, Ann A Jakubowski, MD, PhD, Molly Maloy, BA, Joseph G. Jurcic, MD, Suresh C. Jhanwar, PhD, Cyrus V. Hedvat, MD, PhD, Sergio Giralt, MD, Esperanza B. Papadopoulos, MD

Blood (2012) 120 (21): 2038.

https://doi.org/10.1182/blood.V120.21.2038.2038

Published: 2012

NARROW

Despite High Rates of Remission, Treatment of IDH-Mutant AML with Hypomethylating Agents and Venetoclax Is Associated with Frequent Treatment Delays, Modifications, and Transfusions

Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia

How I treat chronic-phase chronic myelogenous leukemia

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies

Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles

Molecular Profiling in Extramedullary Acute Myeloid Leukemia Reveals Distinct Subgroups Defined By Mutations in KIT and RUNX1

Activation Levels of b-Catenin Signaling in Osteoblasts Define a Threshold for the Development of Myeloid Neoplasia of Variable Severity

Clinical Relevant Alterations Identified By Comprehensive Genomic Profiling Can Potentially Improve Therapeutic Option and Change Prognosis in Hematologic Malignancies

Targeting the Osteoblast in Myelodysplasia and Acute Myeloid Leukemia

AUY922, a Heat Shock Protein 90 (Hsp90) Inhibitor, Demonstrates Activity in Patients with Myeloproliferative Neoplasms (MPNs)

Foxo1 Expressed in Osteoblasts Promotes the Leukemogenic Properties of β-Catenin By Activating Notch Signaling

Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts

High-Dose Cytarabine Monotherapy Versus Intermediate Or High-Dose Cytarabine In Combination With Other Agents As Second-Line Salvage Therapy In Patients With Acute Myeloid Leukemia Who Did Not Respond To Initial Induction Therapy

Stem Cell Transplant Versus Chemotherapy in Older Adults with Acute Myelogenous Leukemia In First Remission

Chronic Myeloid Leukemia After Adjuvant Treatment For Breast Cancer: Is It Therapy Related?

Micafungin Versus Posaconazole Anti-Fungal Prophylaxis in Adult Patients with Acute Leukemia Undergoing Induction Chemotherapy

Outcome of Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia and Normal Cytogenetics (NC-AML) According to Presence of FLT-3 Internal Tandem Duplication (FLT-3ITD) At the Time of Diagnosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only